Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Seagen Inc.
Bothell, Washington, United Statesseagen.com ↗
- Ownership
- Public · SGEN
- Employees
- ~2500
- Development stage
- Other
01
Overview
Seagen has four FDA-approved products—Adcetris, Padcev, Tukysa, and Tivdak—across hematologic malignancies and solid tumors. Adcetris alone has annual sales exceeding $1 billion and is approved for six blood cancer types. The company’s pipeline includes additional ADCs and immuno-oncology agents in various clinical stages
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesAntibody-drug conjugates (ADCs)Small molecules
- Industry
- Biotech
02
Partnerships
Takeda Pharmaceutical Company – co-development/commercialization of Adcetris outside US/CanadaAstellas Pharma – co-development of PadcevGenmab – co-development of TivdakMerck & Co. – collaboration on ladiratuzumab vedotin with $1B equity investment in September 2020
Beyond the preview
Go deeper on Seagen Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seagen Inc..